Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

CXCR4 Mutational Status Does Not Impact Outcomes in Patients with Waldenstrom Macroglobulinemia Treated with Proteasome Inhibitors

Jorge J. Castillo, MD, Joshua Gustine, MPH, Maria Demos, Andrew Keezer, BS, Kirsten Meid, MPH, Toni Dubeau, NP, Gloria G Chan, MS, Jiaji Chen, BS, Maria Luisa Guerrera, MD, Amanda Kofides, Manit Munshi, MS, Nicholas Tsakmaklis, Xia Liu, MD, Lian Xu, MS, Guang Yang, PhD, Zachary R Hunter, PhD, Steven P Treon, MD PhD FRCP

Blood (2019) 134 (Supplement_1): 2830.

https://doi.org/10.1182/blood-2019-122349

Published: 2019

Journal Articles

Depth of Response in Waldenstrom Macroglobulinemia

Jonas Paludo, MD, Jithma Prasad Abeykoon, MD, Morie A. Gertz, MD, Prashant Kapoor, MD, Aneel Paulus, MD, Sikander Ailawadhi, Craig B. Reeder, MD, Thomas E. Witzig, MD, Thomas M. Habermann, MD, Anne J Novak, PhD, Francis K. Buadi, MB, CHB, Angela Dispenzieri, MD, Yi Lin, MD PhD, Ronald S. Go, MD, Martha Q. Lacy, MD, Shaji K. Kumar, MD, S. Vincent Rajkumar, MD, Robert A. Kyle, MD, Stephen M. Ansell, MD PhD

Blood (2018) 132 (Supplement 1): 4141.

https://doi.org/10.1182/blood-2018-99-111540

Published: 2018

Journal Articles

Deepening of Response after Completing Rituximab-Containing Primary Therapy in Patients with Waldenstrom Macroglobulinemia

Jorge J. Castillo, MD, Joshua Gustine, MPH, Toni Dubeau, NP, Kirsten Meid, MPH, Andrew Keezer, BS, Lian Xu, MS, Guang Yang, PhD, Zachary R Hunter, PhD, Steven P Treon, MD PhD FRCP

Blood (2018) 132 (Supplement 1): 2887.

https://doi.org/10.1182/blood-2018-99-110675

Published: 2018

Journal Articles

Prospective Phase II Study of Ixazomib, Dexamethasone and Rituximab in Previously Untreated Patients with Waldenström Macroglobulinemia

Jorge J. Castillo, MD, Kirsten Meid, MPH, Joshua Gustine, Toni Dubeau, NP, Patricia Severns, NP, Steven P Treon, MDPhDFRCP

Blood (2017) 130 (Supplement 1): 1487.

https://doi.org/10.1182/blood.V130.Suppl_1.1487.1487

Published: 2017

Journal Articles

Bendamustine and Bortezomib-Containing Regimens Produce Higher Response Rates and More Durable Responses Versus Cyclophosphamide-Based Therapy in Frontline Waldenstrom Macroglobulinemia

Jorge J. Castillo, MD, Joshua Gustine, Kirsten Meid, MPH, Toni Dubeau, NP, Patricia Severns, NP, Steven P Treon, MDPhDFRCP

Blood (2017) 130 (Supplement 1): 1488.

https://doi.org/10.1182/blood.V130.Suppl_1.1488.1488

Published: 2017

Journal Articles

Another bidder (BDR) revisits

Prashant Kapoor

Blood (2017) 129 (4): 398–400.

https://doi.org/10.1182/blood-2016-12-754523

Published: 2017

Journal Articles

Ixazomib, Dexamethasone and Rituximab in Previously Untreated Patients with Waldenström Macroglobulinemia

Jorge J. Castillo, MD, Joshua Gustine, MPH, Kirsten Meid, MPH, Toni Dubeau, NP, Guang Yang, PhD, Lian Xu, Zachary Hunter, PhD, Steven P Treon, MD PhD

Blood (2016) 128 (22): 2956.

https://doi.org/10.1182/blood.V128.22.2956.2956

Published: 2016

Journal Articles

Bortezomib, Dexamethasone and Rituximab in Newly Diagnosed Patients with WaldenströM's Macroglobulinemia: Final Analysis of a Phase 2 Study after a Minimum Follow up of 6 Years

Maria Gavriatopoulou, Ramon Garcia-Sanz, Efstathios Kastritis, MD, Pierre Morel, Marie-Christine Kyrtsonis, MD PhD, Evridiki Michalis, Zafeirios Kartasis, Xavier Leleu, Giovanni Palladini, MD PhD, Alessandra Tedeschi, Dimitra Gika, Giampaolo Merlini, MD, Pieter Sonneveld, Meletios A Dimopoulos

Blood (2016) 128 (22): 2957.

https://doi.org/10.1182/blood.V128.22.2957.2957

Published: 2016

Journal Articles

Long-Term Outcome of a Prospective Study of Bortezomib, Dexamethasone and Rituximab (BDR) in Previously Untreated, Symptomatic Patients with Waldenstrom's Macroglobulinemia

Steven P Treon, MD PhD, Kirsten Meid, MPH, Joshua Gustine, MPH, Christopher J Patterson, MFA, Jeffrey V. Matous, MD, Irene M. Ghobrial, MD, Jorge J Castillo, MD

Blood (2015) 126 (23): 1833.

https://doi.org/10.1182/blood.V126.23.1833.1833

Published: 2015

Journal Articles

Association of a Pro-Inflammatory Axis Comprised By TSP1-TGF-CTGF/CCN2 with a Decrease in Mir-19a-3p in the Pathophysiology of Diabetic Retinopathy

Philippe Alexander Alvarez Dela Cadena, Jose Francisco Calva Moreno, Fabiola Elizabeth Del Carpio-Cano, PhD, Rao Ajaykumar, MD, William J Foster, MDhD, Raul A Dela Cadena, MD

Blood (2015) 126 (23): 5552.

https://doi.org/10.1182/blood.V126.23.5552.5552

Published: 2015

Journal Articles

Association Between a Pro-Inflammatory Axis Comprised By TSP1-TGFβ-CTGF with Three microRNAs, Mir-19a, miR122 and Mir-133a in the Pathophysiology of Diabetic Retinopathy: A Therapeutic Novel Modality

Raul A Dela Cadena, MD, Melissa Lester, BS, Fabiola Del Carpio-Cano, Alina Shevchenko, BS, John St. Angelo, Jeffery Boakye, Leonardo Deutsch, Philippe Alvarez de la Cadena, William Foster, MD PhD

Blood (2014) 124 (21): 2771.

https://doi.org/10.1182/blood.V124.21.2771.2771

Published: 2014

Journal Articles

Evidence that the Axis Comprised of TSP1-TGFβ-CTGF Plays a Major Role In the Pathophysiology of Diabetic Retinopathy:Regulatory Role Of IL-4 and IL-13

Jaime L Loyola, BS, Melissa R Lester, BS, Fabiola E Del Carpio-Cano, Ph.D., Mario C Rico, MD, William Foster, MD, Jeffrey Henderer, MD, Raul A DeLa Cadena, MD

Blood (2013) 122 (21): 4720.

https://doi.org/10.1182/blood.V122.21.4720.4720

Published: 2013

Journal Articles

Phase II Trial In Advanced Waldenstrom Macroglobulinemia (WM) Patients With Bortezomib: Interest Of Addition Of Dexamethasone To Bortezomib On Behalf Of The French CLL/WM Intergroup (NCT 00777738)

Veronique Leblond, MD, Sylvie Chevret, marie Sarah Dilhuydy, Xavier Leleu, MD, PhD, Carole Soussain, MD, Stéphane Leprêtre, MD, Brigitte Dreyfus, Caroline Dartigeas, Beatrice Mahe, Bruno Anglaret, MD, Brigitte Pegourie, MD, Caroline Besson, MD, PhD, Therese Aurran, Anne Vekhoff, MD, Olivier Tournilhac, MD, PhD, Anne Banos, MD, Herve Oya, Julie Lejeune, Pierre Morel

Blood (2013) 122 (21): 4359.

https://doi.org/10.1182/blood.V122.21.4359.4359

Published: 2013

Journal Articles

Primary therapy of Waldenström macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN)

Meletios A. Dimopoulos, Ramón García-Sanz, Maria Gavriatopoulou, Pierre Morel, Marie-Christine Kyrtsonis, Eurydiki Michalis, Zafiris Kartasis, Xavier Leleu, Giovanni Palladini, Alessandra Tedeschi, Dimitra Gika, Giampaolo Merlini, Efstathios Kastritis, Pieter Sonneveld

Blood (2013) 122 (19): 3276–3282.

https://doi.org/10.1182/blood-2013-05-503862

Published: 2013

Includes: Supplemental data

Journal Articles

Thrombospondin-1 (TSP1), Transforming Growth Factor-Beta (TGFb) and Connective Tissue Growth Factor (CTGF) are Involved in the Pathophysiology of Diabetic Retinopathy,

Raul A. De La Cadena, MD, Mario C Rico, MD, Fabiola Del Carpio-Cano, PhD, Fayez Safadi, PhD, Satya P. Kunapuli, PhD, Geoffrey Smith, Omesh Gupta, MD, Jeffrey Henderer, MD, Ann Igbre, MD

Blood (2011) 118 (21): 3275.

https://doi.org/10.1182/blood.V118.21.3275.3275

Published: 2011

Journal Articles

Primary Therapy of Waldenström's Macroglobulinemia (WM) with Weekly Bortezomib, Low-Dose Dexamethasone and Rituximab (BDR): A Phase II Study of the European Myeloma Network

Meletios A. Dimopoulos, Ramón García-Sanz, Maria Gavriatopoulou, Pierre Morel, Marie-Christine Kyrtsonis, Eirini Katodritou, Eurydiki Michalis, Zafiris Kartasis, Xavier Leleu, MD, PhD, Giovanni Palladini, Alessandra Tedeschi, Dimitra Gika, Evangelos Terpos, Giampaolo Merlini, Efstathios Kastritis, Pieter Sonneveld

Blood (2010) 116 (21): 1941.

https://doi.org/10.1182/blood.V116.21.1941.1941

Published: 2010

Journal Articles

Primary Therapy of Waldnestrom's Macroglobulinemia (WM) with Weekly Bortezomib, Low-Dose Dexamethasone and Rituximab (BDR): A Phase II Study of the European Myeloma Network.

Meletios A. Dimopoulos, Ramon García-Sanz, Maria Gavriatopoulou, Pierre Morel, Marie-Christine Kyrtsonis, Efstathios Kastritis, Eirini Katodritou, Eurydiki Michalis, Zafiris Kartasis, Dimitra Gika, Evangelos Terpos, Pieter Sonneveld

Blood (2009) 114 (22): 2886.

https://doi.org/10.1182/blood.V114.22.2886.2886

Published: 2009

Journal Articles

Bone Remodeling in Patients with Relapsed/Refractory Multiple Myeloma Who Receive Lenalidomide-Based Regimens.

Evangelos Terpos, Dimitrios Christoulas, Efstathios Kastritis, Eirini Katodritou, Xenophon Papanikolaou, Maria Roussou, Nikolaos Stavropoulos, Konstantinos Tsionos, Gerassimos A. Pangalis, Konstantinos Zervas, Orhan Sezer, Meletios A. Dimopoulos

Blood (2007) 110 (11): 4745.

https://doi.org/10.1182/blood.V110.11.4745.4745

Published: 2007

Journal Articles

Bortezomib, Dexamethasone and Rituximab (BDR) Is a Highly Active Regimen in the Primary Therapy of Waldenstrom’s Macroglobulinemia: Planned Interim Results of WMCTG Clinical Trial 05-180.

Steven P. Treon, MD, PhD, Jacob D. Soumerai, Christopher J. Patterson, Zachary R. Hunter, Irene M. Ghobrial, MD, Rose Villarreal, MS,PA-C, Michael A. Willen, MD, Thomas J. Myers, MD

Blood (2006) 108 (11): 2765.

https://doi.org/10.1182/blood.V108.11.2765.2765

Published: 2006

Journal Articles

Tobacco Smoke and Elevated Shear Stress Enhance Classical Pathway Complement Activation on Human Endothelial Cells.

Wei Yin, PhD, Jiyeon Kim, BS, Babette B. Weksler, MD, Berhane Ghebrehiwet, DVM, DSc, Ellinor I.B. Peerschke, PhD

Blood (2006) 108 (11): 3934.

https://doi.org/10.1182/blood.V108.11.3934.3934

Published: 2006

NARROW

CXCR4 Mutational Status Does Not Impact Outcomes in Patients with Waldenstrom Macroglobulinemia Treated with Proteasome Inhibitors

Depth of Response in Waldenstrom Macroglobulinemia

Deepening of Response after Completing Rituximab-Containing Primary Therapy in Patients with Waldenstrom Macroglobulinemia

Prospective Phase II Study of Ixazomib, Dexamethasone and Rituximab in Previously Untreated Patients with Waldenström Macroglobulinemia

Bendamustine and Bortezomib-Containing Regimens Produce Higher Response Rates and More Durable Responses Versus Cyclophosphamide-Based Therapy in Frontline Waldenstrom Macroglobulinemia

Another bidder (BDR) revisits

Ixazomib, Dexamethasone and Rituximab in Previously Untreated Patients with Waldenström Macroglobulinemia

Bortezomib, Dexamethasone and Rituximab in Newly Diagnosed Patients with WaldenströM's Macroglobulinemia: Final Analysis of a Phase 2 Study after a Minimum Follow up of 6 Years

Long-Term Outcome of a Prospective Study of Bortezomib, Dexamethasone and Rituximab (BDR) in Previously Untreated, Symptomatic Patients with Waldenstrom's Macroglobulinemia

Association of a Pro-Inflammatory Axis Comprised By TSP1-TGF-CTGF/CCN2 with a Decrease in Mir-19a-3p in the Pathophysiology of Diabetic Retinopathy

Association Between a Pro-Inflammatory Axis Comprised By TSP1-TGFβ-CTGF with Three microRNAs, Mir-19a, miR122 and Mir-133a in the Pathophysiology of Diabetic Retinopathy: A Therapeutic Novel Modality

Evidence that the Axis Comprised of TSP1-TGFβ-CTGF Plays a Major Role In the Pathophysiology of Diabetic Retinopathy:Regulatory Role Of IL-4 and IL-13

Phase II Trial In Advanced Waldenstrom Macroglobulinemia (WM) Patients With Bortezomib: Interest Of Addition Of Dexamethasone To Bortezomib On Behalf Of The French CLL/WM Intergroup (NCT 00777738)

Primary therapy of Waldenström macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN)

Thrombospondin-1 (TSP1), Transforming Growth Factor-Beta (TGFb) and Connective Tissue Growth Factor (CTGF) are Involved in the Pathophysiology of Diabetic Retinopathy,

Primary Therapy of Waldenström's Macroglobulinemia (WM) with Weekly Bortezomib, Low-Dose Dexamethasone and Rituximab (BDR): A Phase II Study of the European Myeloma Network

Primary Therapy of Waldnestrom's Macroglobulinemia (WM) with Weekly Bortezomib, Low-Dose Dexamethasone and Rituximab (BDR): A Phase II Study of the European Myeloma Network.

Bone Remodeling in Patients with Relapsed/Refractory Multiple Myeloma Who Receive Lenalidomide-Based Regimens.

Bortezomib, Dexamethasone and Rituximab (BDR) Is a Highly Active Regimen in the Primary Therapy of Waldenstrom’s Macroglobulinemia: Planned Interim Results of WMCTG Clinical Trial 05-180.

Tobacco Smoke and Elevated Shear Stress Enhance Classical Pathway Complement Activation on Human Endothelial Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only